Crestline Management, LP Dyne Therapeutics, Inc. Transaction History
Crestline Management, LP
- $1.28 Billion
- Q2 2024
A detailed history of Crestline Management, LP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Crestline Management, LP holds 92,390 shares of DYN stock, worth $3.32 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
92,390
Previous 75,000
23.19%
Holding current value
$3.32 Million
Previous $2.13 Million
53.12%
% of portfolio
0.26%
Previous 0.19%
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$288 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$282 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$265 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$229 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$217 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.86B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...